scholarly journals Clinical efficacy and safety of Chinese herbal medicine versus placebo for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis

2021 ◽  
pp. 102691
Author(s):  
Chan Xiong ◽  
Yu Li ◽  
Guangtong Zhuang ◽  
Yan Zeng ◽  
Hua Wei ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Herbal Medicine ◽  
Pulmonary Disease ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Chronic Obstructive ◽  
Efficacy And Safety ◽  
Obstructive Pulmonary Disease ◽  
Chinese Herbal

scholarly journals Chinese Herbal Medicine Versus Placebo for the Treatment Of Chronic Obstructive Pulmonary Disease

Medicine ◽  
2019 ◽  
Vol 98 (35) ◽  
pp. e17002 ◽  
Author(s):  
Chan Xiong ◽  
Yu Li ◽  
Yan Zeng ◽  
Hua Wei ◽  
Guang-tong Zhuang ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Herbal Medicine ◽  
Pulmonary Disease ◽  
Chinese Herbal Medicine ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Chinese Herbal

scholarly journals Dissection of Pharmacological Mechanism of Chinese Herbal Medicine Yihuo Huatan Formula on Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Xia-Wei Zhang ◽  
Wei Liu ◽  
Hong-Li Jiang ◽  
Bing Mao
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Herbal Medicine ◽  
Pulmonary Disease ◽  
Chinese Herbal Medicine ◽  
Chronic Obstructive ◽  
Systems Pharmacology ◽  
Working Mechanism ◽  
Obstructive Pulmonary Disease ◽  
Network Analyses ◽  
Chinese Herbal

Abstract Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases. Yihuo Huatan Formula (YHF), as a proven Chinese Herbal Medicine (CHM), has been verified to be effective in the treatment of stable COPD through years’ of practice. Nevertheless, its working mechanism is still unclear. We sought to systematically decipher the mechanism of YHF for treating stable COPD using systems pharmacology-based method that integrates pharmacokinetic screening, target prediction, network analyses, GO and KEGG enrichment analyses. Firstly, a total of 1267 chemicals out of 15 herbal components were included in YHF chemical database. Among them, 180 potential active molecules were screened out through pharmacokinetic evaluation. Then 258 targets of the active molecules were predicted, of which 84 were chosen for further analyses. Finally, the network analyses and GO and KEGG enrichment methods suggested a therapeutic effect of YHF on the alleviation of airway inflammation, decrease of mucus secretion, maintenance of immune homeostasis and benefit of COPD comorbidities, by regulating multiple targets and pathways. The systems pharmacology-based approach helps to understand the underlying working mechanism of YHF in stable COPD from a holistic perspective, and offers an exemplification for systematically uncovering the action mechanisms of CHM.

scholarly journals Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease

Medicine ◽  
2016 ◽  
Vol 95 (20) ◽  
pp. e3702 ◽  
Author(s):  
Vincent C.H. Chung ◽  
Xinyin Wu ◽  
Polly H.X. Ma ◽  
Robin S.T. Ho ◽  
Simon K. Poon ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Herbal Medicine ◽  
Fluticasone Propionate ◽  
Pulmonary Disease ◽  
Chinese Herbal Medicine ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Chinese Herbal

scholarly journals Safety of Chinese Herbal Medicine for Chronic Obstructive Pulmonary Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
Meaghan Coyle ◽  
Johannah Linda Shergis ◽  
Shaonan Liu ◽  
Lei Wu ◽  
Anthony Lin Zhang ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Adverse Event ◽  
Herbal Medicine ◽  
Adverse Events ◽  
Pulmonary Disease ◽  
Chinese Herbal Medicine ◽  
Systematic Evaluation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Chinese Herbal

Chinese herbal medicine (CHM) is increasingly used by patients with chronic obstructive pulmonary disease (COPD); however, there has been no systematic evaluation of its safety. This review examined the adverse events (AEs) reported in clinical studies of CHM for COPD. Five English databases (PubMed, Embase, CINAHL, AMED, and CENTRAL) and four Chinese databases (CBM, CNKI, CQVIP, and Wanfang Data) were searched from inception to May 2013. Adverse event data, including nature, severity, author-assigned causality, management, and outcome, were extracted from included studies. Descriptive statistics were used for the rate of adverse events. Of the 152 included studies, AEs were reported in 47 studies. The rate of adverse events was slightly lower in the CHM groups compared with controls (84 events in 5,909 participants, 1.4% versus 102 events in 5,676 participants, 1.8%). The most frequently reported adverse event was nausea (28 cases in the CHM groups and 19 cases in the control groups), which was more common in studies where CHM was combined with pharmacotherapy to treat acute exacerbation of COPD. Other frequent adverse events were abdominal discomfort, dry mouth, and dizziness. Detailed information about the adverse events was scant. Overall, CHM appears to be well tolerated in people with COPD.

Sign in / Sign up

Export Citation Format

Share Document